Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer - Takeaways - MDSpire

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • By

  • June 24, 2026

  • 4 min

Share

  • 1

    The FDA approved sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer.

  • 2

    The approval is based on results from the ASCENT-03 and ASCENT-04 clinical trials led by Sara Tolaney, MD, MPH.

  • 3

    Sacituzumab govitecan significantly improved progression-free survival compared to standard chemotherapy in both trials.

  • 4

    In ASCENT-03, patients treated with sacituzumab govitecan had a median progression-free survival of 9.7 months.

  • 5

    ASCENT-04 showed that the combination of sacituzumab govitecan and pembrolizumab resulted in an 11.2 month median progression-free survival.

Original Source(s)

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

  • by

  • June 24, 2026

Related Content

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

  • 1 min